Yuankai Shi

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Yuankai Shi, Joseph S. K. Au, Sumitra Thongprasert et al. · Journal of Thoracic Oncology · 2014 · 1.5K citations · Full text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.1K citations

Oncology, Phase 2B, Pathology +8

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 591 citations · Full text

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 347 citations